Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
HGH Fragment 176-191: a research sample of the C-terminal fragment of growth hormone (amino acids 176-191), RUO, lyophilized, COA per LOT. Studied for lipolysis without affecting glucose levels; not AOD-9604 and not a finished pharmaceutical product.
Size: 5 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 250 mcg once daily (AM, fasted) | Starting dose |
| Typical regimen | 250 mcg twice daily (≈500 mcg per day) | Increase if needed |
| Maximum in schedule | up to 500 mcg per day, ≈4-week cycle | Maximum in this schedule |
Share your experience
No reviews yet. Tell others what you think of this product.
In short: HGH Fragment 176-191 on the Longeva hub is a research sample of the C-terminal fragment of human growth hormone (somatotropin), supplied as a lyophilized powder with research use only (RUO) status. It is not a finished pharmaceutical product and not a dietary supplement, only raw material for laboratory protocols.
Search queries for "HGH Fragment 176-191" and "AOD-9604" often treat the two names as interchangeable, though structurally they are not the same molecule. AOD-9604 is a separate, stabilized compound with an added N-terminal tyrosine (Tyr-fragment 176-191), sold by some suppliers under its own name. This page lists the unmodified C-terminal fragment of growth hormone (amino acids 176-191), not AOD-9604. The distinction, and what the research on both forms actually found, is covered in the blog review.
The full growth hormone molecule drives both lipolysis (fat breakdown) and tissue growth, and also raises glucose and IGF-1 levels. In preclinical models, fragment 176-191 reproduced the lipolytic action through beta-3 adrenergic receptors, without the hyperglycemic and growth-stimulating effects that come with the full molecule. Several placebo-controlled human trials found the compound well tolerated with no serious adverse events, though these studies did not confirm a consistent, clinically meaningful reduction in body weight. The full reference list and a detailed walk-through of the preclinical and clinical data are in the HGH Fragment 176-191 wiki entry.
Lyophilized powder in a glass vial, 5 mg fill. Store dry, cool, and protected from light per your lab's own SOP. Log receiving conditions, reconstitution, and subsequent storage in your internal batch record; the general research dosing protocol is described separately in the dosing reference.
COAs are issued by independent third-party labs; a report confirms the analytics at the time of testing, not the medical status of the material.
| Query / resource | Where |
|---|---|
| HGH Fragment 176-191 vs AOD-9604 | research review on the blog |
| Wiki: HGH Fragment 176-191 | molecule reference |
| Dosing protocol (research) | dosing reference |
| Another metabolic peptide in the catalog | PXL770 |
Reference material. Not medical advice. This sample is intended for laboratory research use only (RUO). AOD-9604 refers to a separate compound and is not a product sold under that name on this page.